The GLP-1 Podcast Show - Dr. Richard DiMarchi: The Evolution of GLP-1 Science | Ep. 10

In this episode of The GLP-1 Podcast Show, Dr. Richard DiMarchi, Distinguished Professor of Chemical Biology and Gill Chair in Biomolecular Sciences at Indiana University, speaks with Areesha Moiz about the scientific foundations behind GLP-1 therapies and the evolution of obesity pharmacotherapy. The discussion covers peptide engineering, glucagon- and GIP-based multiagonists, triple-agonist development, therapeutic innovation, and future directions in obesity medicine. Listen now on all major platforms.

What you’ll learn: 

• GLP-1 drug evolution
• Multiagonist therapy design
• Glucagon in obesity
• GIP therapeutic role
• Future obesity treatments

Meet the guest:

Dr. Richard DiMarchi is a Distinguished Professor at Indiana University and a recognized leader in peptide therapeutics, diabetes research, and obesity medicine. His work contributed to major advances in insulin, glucagon, and multiagonist therapies, while also helping establish several biotechnology companies. Dr. DiMarchi continues to advance innovation in the treatment of metabolic diseases through research and translational science. Listen to Dr. Richard DiMarchi on The GLP-1 Podcast Show, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!